BEAM compared with PACB: revenue, margins and what each company keeps, and the suppliers and customers both name

BEAMBeam Therapeutics Inc.

Mkt capRevenueRevenue

PACBPacific Biosciences of California, Inc.

Mkt capRevenueRevenue

Compare

BEAMBeam Therapeutics Inc.

PACBPacific Biosciences of California, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BEAM

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.3%▲+9.42%×0.71

May 7 '26±9.2%▼−2.69%×0.29

Q1 FY26±19.4%▲+13.98%×0.72

Q3 FY25±11.8%▼−6.23%×0.53

PACB

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±37.4%▼−10.38%×0.28

Q1 FY26±12.1%▼−14.55%×1.21

= impliedBEAM realized, solidPACB realized, hatchedOne scale, both sides: full bar = 38%× = |realized| ÷ impliedSource: market data

Feb 13 '26

±16.5%

▼−7.07%

×0.43

Jan 12 '26±10.9%▲+3.61%×0.33

BEAMBeam Therapeutics Inc.

26.27▼−3.54%

Mkt cap$2.8BRevenue$490,000Q2 FY26Revenue$140MFY25

PACBPacific Biosciences of California, Inc.

2.43▼−6.91%

Regular sessionNov 2 '26

Mkt cap$809.7MRevenue$39MQ2 FY26Revenue$160MFY25

Compare

Regular sessionNov 2 '26

BEAMBeam Therapeutics Inc.

PACBPacific Biosciences of California, Inc.

26.27▼−3.54%

Price

2.43▼−6.91%

$2.8B

Mkt cap

$809.7M

Q2 FY26$490,000

Revenue

$39MQ2 FY26

FY25$140M

Revenue

$160MFY25

BEAM26.27▼−3.54%vsPACB2.43▼−6.91%Regular sessionNov 2 '26